The present invention relates to a pharmaceutical composition for preventing or treating fibrosis, containing a pheophorbide compound as an active ingredient. The pharmaceutical composition can effectively inhibit fibrosis of tissues by inhibiting signaling of TGF-β which causes fibrosis and inhibiting activation and expression of collagen and fibronectin, and is significantly superior in the anti-fibrotic activity compared to nintedanib or pirfenidone, which are commercially available therapeutic agents for pulmonary fibrosis, and therefore may be widely used in the prevention or treatment of fibrosis.

The present disclosure relates to pharmaceutical compositions comprising PTEN inhibitors and methods of treating or preventing bone marrow loss in subjects in subjects in need thereof. The compositions and methods of this disclosure are useful in treating or preventing bone marrow loss associated with exposure to nuclear radiation or chemotherapeutic treatment.

The present disclosure relates to pharmaceutical compositions comprising PTEN inhibitors and methods of treating or preventing bone marrow loss in subjects in subjects in need thereof. The compositions and methods of this disclosure are useful in treating or preventing bone marrow loss associated with exposure to nuclear radiation or chemotherapeutic treatment.

A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor:

##STR00001##

wherein R.sup.111, R.sup.121, R.sup.131, and R.sup.141 each independently represent a monovalent organic group; p, q, r, and s each independently represent an integer of 0 or 1 to 4; in the case where two or more R.sup.111, R.sup.121, R.sup.131, and R.sup.141 are present, they may be identical to or different from one another or may be bonded to one another to form a ring; A.sup.101 represents a monovalent organic group; and A.sup.102 represents a hydrogen atom or a monovalent organic group). In the method, a photosensitive dye can be decomposed using an energy beam which can penetrate deeper into a living body than near-infrared light and activate the photosensitive dye.

The present disclosure provides nanoparticles including laminarin and a near-infrared responsive photosensitizer covalently bonded thereto, and a composition for preventing, diagnosing, or treating arteriosclerosis comprising the same as an active ingredient. According to the present disclosure, not only the atherosclerotic plaque targeting and plaque-penetrating properties can be enhanced as compared to conventional photodynamic therapy, thus capable of being usefully used for in vivo imaging of atherosclerotic plaques, but also the size of atherosclerotic plaques is reduced by inducing apoptosis of macrophages in atherosclerotic plaques, thus capable of stabilizing atherosclerotic plaques. Therefore, the composition comprising the nanoparticles of the present disclosure as an active ingredient is expected to be usefully used for the prevention, diagnosis and/or treatment of arteriosclerosis, in that photodynamic therapy and image diagnostic of arteriosclerosis can be performed simultaneously or sequentially.

Disclosed is a family of corroles for their use in the treatment of an infection by poxvirus.

Disclosed is a family of corroles for their use in the treatment of an infection by poxvirus.

Disclosed is a family of corroles for their use in the treatment of an infection by poxvirus.

Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I)

##STR00001##

or a pharmaceutically or veterinary acceptable salt thereof, wherein:
R.sub.1 R.sub.2 and R.sub.3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof,

##STR00002##

wherein R.sub.5 and R.sub.6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed. These combinations, single pharmaceutical compositions and kits of parts are for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof

Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I)

##STR00001##

or a pharmaceutically or veterinary acceptable salt thereof, wherein:
R.sub.1 R.sub.2 and R.sub.3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof,

##STR00002##

wherein R.sub.5 and R.sub.6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed. These combinations, single pharmaceutical compositions and kits of parts are for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof